Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Avectas, Vycellix Enter Next-Gen Cell & Gene Mfg. Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Avectas, Vycellix Enter Next-Gen Cell & Gene Mfg. Pact

Aims to advance solutions for the optimized manufacture of Cell & Gene therapies

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Avectas, a cell engineering technology business and Vycellix, Inc. an immuno-discovery cell & gene therapy company, have entered into a collaboration to develop new approaches for cell-based immunotherapeutic products.  

The companies will collaborate on the delivery of Vycellix’s RNA immunomodulator VY-M using Avectas’ cell engineering platform, Solupore to address current limitations for cell-based therapies, in particular the need to accelerate the manufacturing process, reduce costs, and ultimately improve patient outcomes.

Both companies are partners within NextGenNK, a newly established competence center for development of next-generation NK cell-based cancer immunotherapies based at Karolinska Institutet, Stockholm, Sweden.  Avectas and Vycellix will further expand their collaboration within the NextGenNK constellation.

“We are delighted to partner with Vycellix and join forces in the development of novel cell-based products,” says Michael Maguire, PhD, CEO of Avectas. “We believe Solupore® will play a critical role in the manufacture of cell-based therapies and will support a path towards effective patient outcomes.”

Vycellix’s President, Douglas Calder, said, “Solupore represents a new paradigm for delivery of transgenes, and our initial studies will evaluate Solupore to deliver our new product candidate, VY-M, to T cells and NK cells.  We expect to accelerate the expansion-time of T cells and NK cells by decreasing the non-dividing lag time, resulting in much shorter “vein-to-vein” delivery-time to patients.” 

The studies will be conducted at Avectas’ Dublin-based facility and at Karolinska Institutet, Stockholm, Sweden.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics